City of Hope

Thomas Jefferson University

Joshua Michael Donaldson

John C Williams

Kendra Nicole Avery

Cindy Zer

Ulrich Rodeck

Csaba Kari

Jun Xie

David A Horne

Yuelong Ma

Krzysztof Bzymek

Heng Wei Chang

In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker.

Development of masked therapeutic antibodies to limit off-target effects

Antibodies and meditopes that bind to the antibodies are provided, as well as complexes, compositions and combinations containing the meditopes and antibodies, and methods of producing, using, testing, and screening the same, including therapeutic and diagnostic methods and uses.

Meditopes and meditope-binding antibodies and uses thereof

In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.

Development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies

Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies

Growing community of inventors

Lumberton, NJ, United States of America

Joshua Michael Donaldson